Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies for the biotech industry, has hired Vijay Surapaneni as its Vice President of Biomanufacturing Operations. This is a new position and is a part of the senior management team.
Aldevron, a global leader in the custom development and manufacture of plasmid DNA, protein, mRNA and antibodies for the biotech industry, is hosting its second Breakthrough Symposium with the theme “Pioneering Biotech,” September 28-30, 2020, in Fargo, N.D., home to Aldevron’s headquarters and main campus.
FARGO, N.D. (February 12, 2019)—Aldevron, a global leader in the custom development and manufacture of plasmid DNA, proteins, mRNA and antibodies to the biotech industry, announced today the addition of DasherGFP® (green fluorescent protein) mRNA to its off-the-shelf, product portfolio.
In June of 2019, Aldevron announced its massive 14-acre campus expansion. The construction began with a groundbreaking ceremony in August of 2019, launching the buildout of the campus’ second GMP manufacturing facility. This 189,000 square-foot, two-story building is slated to increase Aldevron’s GMP and GMP-Source production capacity up to 10 times its current output. In December of 2019, a major milestone was reached when structural steel beams were installed (pictured).
Aldevron client and partner, Calviri, testing vaccine to prevent cancer in trial using 800 dogs
Aldevron has the privilege of working with thousands of clients trying to solve the world’s biggest health challenges and cancer is at the top of the list. Finding a preventative therapy has long been the goal. Our partner, Calviri, is testing a vaccine in a canine trial that could lead to a treatment for humans.
Aldevron, Nature Technology Corporation team up to offer Nanoplasmids™ for gene therapy manufacturing
Aldevron has announced the immediate availability of NanoplasmidsTM and antibiotic-free RNA-OUT technology for use in gene therapy manufacturing. Through a license agreement with Nature Technology Corporation (NTC), Aldevron can now provide its clients the option of using NTC’s plasmid technology to provide a more efficient system for manufacturing viral vectors used in gene and cell therapy.
Diane Rogers has joined Aldevron as its Senior Vice President Commercial Development. In her role, Rogers will be responsible for leading the worldwide sales and marketing activities to support Aldevron’s business units.
PTC Therapeutics Establishes Strategic Collaboration with Aldevron to Support GMP Plasmid Manufacturing
PTC Therapeutics, Inc., is collaborating with Aldevron to secure GMP manufacturing capacity for PTC's gene therapy portfolio. This portfolio includes the Friedreich ataxia and Angelman syndrome programs in PTC's gene therapy pipeline.
Aldevron announces GMP gene synthesis service to support neoantigen-based oncology research and other applications
Aldevron has added GMP gene synthesis to its array of services. This expanded capability will be used primarily to support Aldevron’s clients who require rapid GMP gene synthesis for novel cancer treatments based on neoantigens. The company noted the service is not suited for routine, research-grade synthesis, for which Aldevron will continue using outside providers.
News report courtesy Forum Communication, written by Barry Amundson. Published August 29, 2019
Tax incentive supporters are putting the pressure on to show that programs being offered to businesses and developers are not only going to eventually provide impressive property tax payments but also provide positive ripple effects in the community.